Amendment No. 1 to Engagement Letter between DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (February 21, 2017)

Contract Categories: Business Operations › Advisory Agreements
Summary

DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC have agreed to extend the term of their original engagement letter, dated January 24, 2017, by an additional 30 days. All other terms and conditions of the original agreement remain unchanged and in effect. This amendment is signed by authorized representatives of both parties.

View More
EX-10.3 6 f8k0417ex10iii_delmarpharma.htm AMENDMENT NO. 1, DATED FEBRUARY 21, 2017 BETWEEN DELMAR PHARMACEUTICALS, INC. AND RODMAN & RENSHAW, A UNIT OF H.C. WAINWRIGHT & CO., LLC.

Exhibit 10.3

 

February 21, 2017

 

STRICTLY CONFIDENTIAL

 

Jeffrey Bacha

Chairman & CEO

DelMar Pharmaceuticals, Inc.

Suite 720 - 999 West Broadway

Vancouver, British Columbia

Canada V5Z 1K5

 

Dear Mr. Bacha:

 

This letter shall serve as an amendment (the “Amendment”) to that certain engagement letter (the “Original Letter”), dated as of January 24, 2017, by and between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Original Letter.

 

Wainwritght and the Company hereby mutually agree to extend the Term of the Original Letter pursuant to Section B. for an additional 30 days.

 

Except as modified by this letter, the terms, provisions and requirements of the Original Letter shall remain the same and in full force and effect in accordance with the terms and provisions thereof.

 

  Very truly yours,
     
  H.C. WAINWRIGHT & CO., LLC
     
  By: /s/ Edward D. Silvera
    Name: Edward D. Silvera
    Title:   COO

 

Accepted and Agreed:
     

DELMAR PHARMACEUTICALS, INC.
     
 By: /s/ Jeffrey A. Bacha  
 Name: Jeffrey A. Bacha
Title Chairman & CEO